SLOW-K
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Apr 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SLOW-K is an extended-release oral tablet containing potassium, approved in 1975 by Novartis. The product treats potassium deficiency (hypokalemia) by providing sustained delivery of potassium ions over time. It is a small-molecule electrolyte replacement therapy.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and shift toward defensive commercial strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SLOW-K offers limited career growth opportunities given its mature lifecycle and approaching loss of exclusivity. Roles on this product tend to focus on defensive commercial strategies, cost optimization, and supply chain management rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on SLOW-K at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.